224 related articles for article (PubMed ID: 24566868)
1. RSF1 is a positive regulator of NF-κB-induced gene expression required for ovarian cancer chemoresistance.
Yang YI; Ahn JH; Lee KT; Shih IeM; Choi JH
Cancer Res; 2014 Apr; 74(8):2258-69. PubMed ID: 24566868
[TBL] [Abstract][Full Text] [Related]
2. lncRNA-PRLB Confers Paclitaxel Resistance of Ovarian Cancer Cells by Regulating RSF1/NF-κB Signaling Pathway.
Zhao Y; Hong L
Cancer Biother Radiopharm; 2021 Mar; 36(2):202-210. PubMed ID: 33156701
[No Abstract] [Full Text] [Related]
3. Rsf-1 Influences the Sensitivity of Non-Small Cell Lung Cancer to Paclitaxel by Regulating NF-κB Pathway and Its Downstream Proteins.
Chen X; Sun X; Guan J; Gai J; Xing J; Fu L; Liu S; Shen F; Chen K; Li W; Han L; Li Q
Cell Physiol Biochem; 2017; 44(6):2322-2336. PubMed ID: 29258089
[TBL] [Abstract][Full Text] [Related]
4. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
5. The biphasic role of NF-kappaB in progression and chemoresistance of ovarian cancer.
Yang G; Xiao X; Rosen DG; Cheng X; Wu X; Chang B; Liu G; Xue F; Mercado-Uribe I; Chiao P; Du X; Liu J
Clin Cancer Res; 2011 Apr; 17(8):2181-94. PubMed ID: 21339307
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of Eag1 Expression by RNA Interference Increases Chemosensitivity to Cisplatin in Ovarian Cancer Cells.
Hui C; Lan Z; Yue-li L; Li-lin H; Li-lin H
Reprod Sci; 2015 Dec; 22(12):1618-26. PubMed ID: 26079730
[TBL] [Abstract][Full Text] [Related]
7. Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer.
Horio M; Kato T; Mii S; Enomoto A; Asai M; Asai N; Murakumo Y; Shibata K; Kikkawa F; Takahashi M
Cancer Med; 2012 Oct; 1(2):218-29. PubMed ID: 23342271
[TBL] [Abstract][Full Text] [Related]
8. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
9. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.
Liu J; Viswanadhapalli S; Garcia L; Zhou M; Nair BC; Kost E; Rao Tekmal R; Li R; Rao MK; Curiel T; Vadlamudi RK; Sareddy GR
Oncotarget; 2017 Jul; 8(30):50002-50014. PubMed ID: 28654894
[TBL] [Abstract][Full Text] [Related]
11. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC
J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412
[TBL] [Abstract][Full Text] [Related]
12. NF-κB1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer.
Shuang T; Wang M; Zhou Y; Shi C; Wang D
Oncotarget; 2017 Apr; 8(15):24853-24868. PubMed ID: 28206956
[TBL] [Abstract][Full Text] [Related]
13. Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer.
Wu X; Zhao J; Ruan Y; Sun L; Xu C; Jiang H
Cell Death Dis; 2018 Oct; 9(11):1102. PubMed ID: 30375371
[TBL] [Abstract][Full Text] [Related]
14. ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2.
Luo Q; Wu X; Zhang Y; Shu T; Ding F; Chen H; Zhao P; Chang W; Zhu X; Liu Z
Cancer Lett; 2018 Jul; 427():9-17. PubMed ID: 29660381
[TBL] [Abstract][Full Text] [Related]
15. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers.
Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ
Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322
[TBL] [Abstract][Full Text] [Related]
16. Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
Kim M; Lu F; Zhang Y
Cell Rep; 2016 Sep; 17(1):275-288. PubMed ID: 27681437
[TBL] [Abstract][Full Text] [Related]
17. The transcriptional coactivator CREB-binding protein cooperates with STAT1 and NF-kappa B for synergistic transcriptional activation of the CXC ligand 9/monokine induced by interferon-gamma gene.
Hiroi M; Ohmori Y
J Biol Chem; 2003 Jan; 278(1):651-60. PubMed ID: 12403783
[TBL] [Abstract][Full Text] [Related]
18. Treatment with β-elemene combined with paclitaxel inhibits growth, migration, and invasion and induces apoptosis of ovarian cancer cells by activation of STAT-NF-κB pathway.
Xiaomeng F; Lei L; Jinghong A; Juan J; Qi Y; Dandan Y
Braz J Med Biol Res; 2020; 53(6):e8885. PubMed ID: 32401925
[TBL] [Abstract][Full Text] [Related]
19. Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB pathway.
Zou W; Ma X; Hua W; Chen B; Cai G
Oncol Rep; 2015 Dec; 34(6):3256-63. PubMed ID: 26503358
[TBL] [Abstract][Full Text] [Related]
20. HER2 decreases drug sensitivity of ovarian cancer cells via inducing stem cell-like property in an NFκB-dependent way.
Wang W; Gao Y; Hai J; Yang J; Duan S
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30314995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
